Amgen Inc. (AMGN)
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline
Amgen generated 20% revenue growth in its most recent quarter. The business has several fast-growing drugs showing double-digit growth despite generating over $200 million in quarterly sales.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen: Q2 Earnings Review: Still Solid, But Wait For MariTide Data Goes On
Amgen Inc., the Thousand Oaks headquartered Pharma giant, reported its Q2 2024 earnings on August 6th. My last coverage of Amgen was in May after Q1 earnings, and I awarded the stock a “buy” recommendation. Q2 earnings were generally solid, with the Horizon assets bedding in well, meaning revenues grew 20% year-on-year.
Amgen Stock Slides on Lowered Guidance
Amgen (AMGN) shares tumbled 5% Wednesday after the drug developer lowered its full-year earnings guidance.
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
On Tuesday, Amgen Inc. AMGN reported mixed second-quarter results.
Why Amgen Stock Is Down Today Despite Solid Q2 Results
The pharmaceutical company's second-quarter numbers were roughly in line with expectations. Amgen's slight earnings miss, however, was enough to spark a sizeable sell-off.
Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat
Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024.
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen NASDAQ: AMGN is a biotechnology firm that has made its way into the weight loss treatment battle. The company's shares have performed relatively well in 2024, providing a total return of 16%, outpacing its sector and the market.
Amgen Inc. (AMGN) Q2 2024 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN ) Q2 2024 Results Conference Call August 6, 2024 4:30 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Bob Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations Vikram Karnani - EVP & President, Global Commercial Operations & Medical Affairs (Rare Disease) Jay Bradner - EVP, Research and Development & Chief Scientific Officer Peter Griffith - EVP & CFO Conference Call Participants Yaron Werber - TD Cowen Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Markets Mike Yee - Jefferies Umer Raffat - Evercore ISI Jay Olson - Oppenheimer Mohit Bansal - Wells Fargo Gregory Renza - RBC Capital Markets Chris Raymond - Piper Sandler Carter Gould - Barclays Terence Flynn - Morgan Stanley Chris Schott - JPMorgan Kripa Devarakonda - Truist Securities James Shin - Deutsche Bank Gary Nachman - Raymond James Operator My name is Julianne, and I will be your conference facilitator today for Amgen's Second Quarter 2024 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise.
Amgen (AMGN) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amgen (AMGN) Q2 Earnings and Revenues Beat Estimates
Amgen (AMGN) came out with quarterly earnings of $4.97 per share, beating the Zacks Consensus Estimate of $4.93 per share. This compares to earnings of $5 per share a year ago.
